Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Bearish -65

FDA understated risk of heart damage from Moderna COVID vaccine, new study suggests - new.finalcall.com

📉 A new study in Vaccines found Moderna's COVID-19 vaccine caused 8%-52% more hospitalizations for myocarditis/pericarditis than it prevented for males aged 18-25.

🔬 The FDA's 2022 benefit-risk assessment is criticized for using uniform hospitalization rates across ages 18-45 and ignoring the protective effects of prior natural infection.

📊 Reanalysis by lead author Paul Bourdon, Ph.D., shows a benefit-risk ratio of roughly 0.67 compared to the FDA's estimated 43:1 favoring vaccination.

⚠️ Experts claim the FDA model understated myocarditis risks and overestimated vaccine effectiveness, potentially tilting the risk-benefit picture unfairly toward approval.

🌍 International data supports these findings, including a 2024 Nature Communications study showing a 620% higher myocarditis risk in South Korea and high fatality rates in Japan.

🏥 The FDA has since required Pfizer and Moderna to revise vaccine labels with detailed warnings about heart damage risks following similar safety concerns.

📝 Researchers urge the FDA to adopt stratified recommendations based on age, sex, prior infection, and comorbidity status rather than a one-size-fits-all approach.

Bullish Signals
  • The study provides a detailed reanalysis using the FDA's own framework but with more realistic assumptions, offering transparency into how original models may have been flawed.
  • The research highlights that approximately 70% of young men had prior natural immunity, which offers protection equivalent to vaccination but was excluded from the FDA's assessment.
  • The findings align with other global studies and a 2024 National Academies report confirming a causal link between mRNA vaccines and myocarditis, reinforcing independent scientific consensus.
Risk Factors
  • Moderna's vaccine is associated with significantly higher hospitalization rates for heart inflammation (myocarditis/pericarditis) than COVID-19 prevention in young males aged 18-25.
  • The FDA's original risk-benefit analysis may have understated myocarditis risks and overestimated vaccine effectiveness, leading to potentially unsafe recommendations.
  • Healthy young men with prior COVID-19 infection faced increased risks of serious heart injury after vaccination, contradicting claims of safety for this demographic.
  • Critics allege the FDA worked backward to find an analysis supporting approval despite evidence that risks outweighed benefits for healthy young males.
  • The study suggests that vaccine mandates for healthy young people may have been inappropriate given the minuscule danger of COVID-19 itself in this age group.
Full Analysis
A study published in the journal Vaccines suggests that Moderna's COVID-19 vaccine (mRNA-1273) presented greater risks than benefits for males aged 18-25, contradicting the FDA's 2022 risk-benefit analysis. The research found that among this demographic, the vaccine was associated with 8% to 52% more hospitalizations for myocarditis and pericarditis than the number of COVID-19 hospitalizations it prevented during a five-month window. Lead author Paul S. Bourdon, Ph.D., and epidemiologist M. Nathaniel Mead argue that the FDA's original model understated risks by assuming uniform hospitalization rates for males aged 18-45 rather than stratifying them correctly. Additionally, the FDA analysis omitted the significant benefits of natural immunity from prior COVID-19 infection, which affected approximately 70% of young men at the time of assessment, thereby skewing the benefit-risk ratio. The new analysis indicates that the FDA's model likely underestimated myocarditis rates and overestimated vaccine effectiveness against hospitalization. Experts cited in the article suggest that the FDA may have worked backward to find an analysis supporting approval despite evidence that risks outweighed benefits for healthy young men, particularly those with prior infections who faced increased heart injury risks. The study calls for more rigorous benefit-risk assessments that account for age, sex, prior infection status, and comorbidities. It highlights international precedents where France suspended Moderna's vaccine use and cites other global studies linking mRNA vaccines to severe myocarditis and pericarditis, noting that the FDA has since required revised labels warning of heart damage risks.